Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vericel Corporation (VCEL)

Vericel Corporation (VCEL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,950,134
  • Shares Outstanding, K 50,574
  • Annual Sales, $ 237,220 K
  • Annual Income, $ 10,360 K
  • EBIT $ 7 M
  • EBITDA $ 12 M
  • 60-Month Beta 1.17
  • Price/Sales 7.88
  • Price/Cash Flow 130.34
  • Price/Book 6.40

Options Overview Details

View History
  • Implied Volatility 72.61% (+3.34%)
  • Historical Volatility 41.49%
  • IV Percentile 83%
  • IV Rank 52.46%
  • IV High 95.56% on 04/08/25
  • IV Low 47.27% on 01/22/25
  • Expected Move (DTE 4) 7.95 (20.61%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 22
  • Volume Avg (30-Day) 170
  • Put/Call OI Ratio 0.41
  • Today's Open Interest 927
  • Open Int (30-Day) 780
  • Expected Range 30.61 to 46.51

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.45
  • Number of Estimates 3
  • High Estimate 0.52
  • Low Estimate 0.39
  • Prior Year 0.38
  • Growth Rate Est. (year over year) +18.42%

Price Performance

See More
Period Period Low Period High Performance
1-Month
34.79 +10.84%
on 12/16/25
41.65 -7.42%
on 01/08/26
+0.18 (+0.47%)
since 12/09/25
3-Month
31.33 +23.06%
on 10/10/25
43.00 -10.33%
on 11/06/25
+5.79 (+17.67%)
since 10/09/25
52-Week
29.24 +31.87%
on 09/25/25
63.00 -38.79%
on 02/05/25
-20.97 (-35.23%)
since 01/08/25

Most Recent Stories

More News
Vericel to Present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026

CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company...

VCEL : 38.56 (-5.33%)
Vericel to Present at the Stephens Annual Investment Conference on Thursday, November 20, 2025

CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company...

VCEL : 38.56 (-5.33%)
Vericel Reports Third Quarter 2025 Financial Results

Record Third Quarter Total Revenue of $67.5 Million MACI Revenue Growth of 25% to $55.7 Million Net Income of $5.1 Million and Adjusted EBITDA Margin of 25% Record Third Quarter Operating...

VCEL : 38.56 (-5.33%)
Vericel to Report Third-Quarter 2025 Financial Results on November 6, 2025

CAMBRIDGE, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company...

VCEL : 38.56 (-5.33%)
Leerink Partners Keeps Their Buy Rating on Vericel (VCEL)

In a report released on October 14, Mike Kratky from Leerink Partners maintained a Buy rating on Vericel, with a price target of $48.00. The company’s shares closed yesterday at $33.59.Elevate Your Investing...

VCEL : 38.56 (-5.33%)
Leerink Partners Remains a Buy on Vericel (VCEL)

Leerink Partners analyst Mike Kratky reiterated a Buy rating on Vericel yesterday and set a price target of $50.00. The company’s shares closed yesterday at $33.74.Elevate Your Investing Strategy: Take...

VCEL : 38.56 (-5.33%)
Vericel to Present at the Wells Fargo Healthcare Conference on Thursday, September 4, 2025

CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company...

VCEL : 38.56 (-5.33%)
Vericel Reports Second Quarter 2025 Financial Results

Total Revenue Growth of 20% to $63.2 Million, with MACI Revenue Growth of 21% to $53.5 Million Gross Margin Increased More than 400 Basis Points to 74% Adjusted EBITDA Growth of 112% to $13.4...

VCEL : 38.56 (-5.33%)
Vericel to Report Second-Quarter 2025 Financial Results on July 31, 2025

CAMBRIDGE, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company...

VCEL : 38.56 (-5.33%)
Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 17, 2025

VCEL : 38.56 (-5.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Vericel Corporation is focused on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two autologous cell therapy products in the United States: Carticel (R) for the treatment of cartilage defects in the...

See More

Key Turning Points

3rd Resistance Point 43.58
2nd Resistance Point 42.54
1st Resistance Point 40.55
Last Price 38.56
1st Support Level 37.52
2nd Support Level 36.48
3rd Support Level 34.49

See More

52-Week High 63.00
Fibonacci 61.8% 50.10
Fibonacci 50% 46.12
Fibonacci 38.2% 42.14
Last Price 38.56
52-Week Low 29.24

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar